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Introduction
An overlap between asthma and OSA is increasingly recognised. Epidemiological studies have shown asthmatics are more likely to report symptoms of sleep disordered breathing such as excessive daytime sleepiness, snoring and apnoeas 1 . Polysomnography (PSG) has M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT been used to demonstrate a high prevalence of OSA in asthma 2 . Approximately 5-10% of asthmatics have severe or difficult to treat asthma (SDTA) that remains problematic despite optimal treatment 3 . The prevalence of OSA has been reported to be as high as 95% in severe steroid dependent asthma 2 and OSA can adversely impact asthma control 1 
. Continuous
Positive Airway Pressure (CPAP) is the gold standard treatment for patients with the OSA syndrome 4 , however the efficacy of this treatment in terms of impact on co-existing asthma symptoms remains unclear.
The mechanisms through which asthma and OSA might interact are complex. Bronchial hyperresponsiveness and airway inflammation are the two key pathophysiological hallmarks of asthma 5 . Studies have also demonstrated that increased airway and systemic inflammation are present in patients with OSA 6,7 . Additionally, CPAP treatment can reduce Fractional Exhaled Nitric Oxide (FENO) 6 and improve markers of systemic inflammation such as C-reactive protein (CRP) 7 . Whether CPAP improves bronchial hyperresponsivness in OSA patients is less clear 8, 9 .
Asthma and OSA have common co-morbidities that include obesity and gastro-oesophageal reflux disease (GORD). These co-morbidities can negatively impact on asthma control 7 . GORD can be precipitated by the large negative intrapleural pressure swings that occur in OSA 7 , and CPAP treatment has been shown to improve reflux symptoms 10 . CPAP has also been shown to improve insulin resistance 11 , which could potentiate weight loss and improve asthma symptoms. The mechanisms through which CPAP could potentially improve asthma symptoms are illustrated in figure 1 .
A high prevalence of OSA has been observed in asthma populations, with negative impact on asthma symptoms and control. CPAP is known to be an effective treatment for OSA in the general population. However, there are reports of patients developing bronchial hyperresponsiveness with CPAP treatment 9 which could clearly have a detrimental impact on asthmatic patients. The aim of this review is to ascertain the effects of CPAP on asthmatic patients with OSA, its tolerability and in particular its impact on asthma-related symptoms and quality of life.
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Methods
This systematic review is registered with PROSPERO (CRD 42017074054). Standard systematic review methodology was used.
Aims
To determine if CPAP treatment of co-existing OSA improves -asthma-related quality of life, symptoms and other related clinical outcomes
Inclusion & exclusion criteria
To be included in this review, studies had to meet the following criteria: 1) A population of asthmatics with co-existing obstructive sleep apnoea. Studies with mixed populations were included if data for asthmatics with co-existing OSA were presented separately.
2) Treatment with CPAP
3) Measurement of ≥ 1 asthma-related clinical outcome
Studies were excluded based on the following criteria: 1) Not written in English 2) Non-adult populations (<18 years)
3) Full text article not available (ie. abstracts, letters, and editorials)
4) Original research/data not included in published article
Search Methodology
Literature search was performed using EMBASE and MEDLINE databases. The search terms included "asthma OR asthmatic" AND "obstructive sleep apnoea/apnea OR OSA" AND "continuous positive airway pressure OR CPAP". All studies up to and including July 2017 were included.
Data Extraction & Assessment of Bias
Two independent reviewers assessed the results of the searches generated in EMBASE and MEDLINE databases. Studies generated from the above searches were assessed as per the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) diagram Studies were assessed for bias by the two reviewers, with any disagreement resolved through discussion. Bias was assessed using the ROBINS-I (Risk of Bias in Non-Randomised Studies of Interventions) 12 , which is based on the Cochrane risk of bias tool for randomised studies.
Data synthesis and analysis
Studies were categorised into groups according to the clinical outcome measured; 1) asthma quality of life, 2) asthma control/symptoms, 3) asthma severity and 4) lung function and physiological measures.
The reviewers judged that there was sufficient data to meta-analyse 1) AQLQ and mini-AQLQ and 2) lung function; Forced Expiratory Volume in 1 second-% predicted (FEV1%pred). RevMan (Review Manager) version 5.3 was used for the meta-analysis. A fixed effects model was used to calculate mean difference in pre and post CPAP values for these outcome measures. A narrative synthesis was used to describe the remaining data, as clinically significant heterogeneity in the measuring of other clinical outcomes precluded meta-analysis.
Results
12 studies met the inclusion/exclusion criteria for this systematic review as illustrated in the PRISMA diagram (figure 2). 8 studies were prospective quasi-experimental studies and 4 were observational. No randomised, placebo-controlled studies were identified. It is important to note that the two cross-sectional studies by Teodorescu et al appear to be based on the same cohort of patients. Although the total data set in one paper was reported M A N U S C R I P T
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as enhanced with subjects from an additional centre, in the subset of patients with asthma and OSA the numbers included are very similar in both studies (136 versus 140, with 75 patients in each study using CPAP).
The mean duration of CPAP for the prospective quasi-experimental studies was 19.5 weeks (range 2-100 weeks). The duration of CPAP in the cross-sectional or retrospective studies ranged from "current treatment" to 5.7 years. There was improved asthma related quality of life in two studies when measured using AQLQ or mini-AQLQ (see table 1 ). Meta-analysis of available Asthma Quality of Life data was possible after combining the results of AQLQ and mini-AQLQ, which have similar scores and clinical interpretation.
Asthma control was reported in 3 studies; 1 study used the ACQ and demonstrated significant improvement post-CPAP, 2 studies used the ACT and 1 demonstrated significant improvement, the other did not. 4 further studies evaluated daytime and/or night-time asthma symptoms with all 4 reporting improvements with CPAP. 1 study demonstrated a non-significant reduction in A&E visits (p=0.058). 1 study found a significant reduction in asthma exacerbation frequency with CPAP (p=0.015) (see table 2 ).
Asthma severity was measured in 3 studies. Methods of measuring severity of asthma included GINA (Global Initiative for Asthma) guidelines, NAEPP (National Asthma Education and Prevention Program) guidelines and a visual analogue score, with each study using a different method. An improvement of asthma severity was seen in all 3 following CPAP (table 3) .
Bronchial airway responsiveness was assessed in 2 studies. One study used the methacholine challenge test and showed no significant improvement with CPAP, the other study assessed airway reversibility and demonstrated a significant improvement with CPAP (table 4) .
6 studies reported changes in FEV 1 with CPAP. 2 studies were excluded from meta-analysis due to lack of sufficient data or a significant difference in the study design. Four studies were combined in a meta-analysis. There was no significant improvement in FEV 1 (5 studies) M A N U S C R I P T
or FEV 1 /FVC ratio (3 studies). Peak expiratory flow rates improved in the 1 study that reported it. Arterial oxygenation and arterial carbon dioxide levels improved in the 1 study that reported this outcome and FENO also improved in 1 study (table 4) .
Meta-Analysis
Mean asthma quality of life scores (AQLQ and mini-AQLQ) improved significantly by 0.59 (95% CI 0.25, 0.92), p=0.0006 with CPAP. No significant improvement was demonstrated in FEV 1 (%pred); 0.32 (95% CI -2.84, 3.47), p=0.84. These results are illustrated using forest plots ( figure 3 ).
Risk of bias
The potential for bias in each study was assessed using the ROBINS-I scale. A high risk of bias due to confounding was present in at least 4/12 studies with unclear evidence in 3/12.
There was also high risk of selection and misclassification bias in 4/12 studies. The overall risk of bias for all 12 studies is illustrated in figure 4 as both a bias graph and bias summary.
Discussion
This systematic review has included all current literature with regards to the impact of CPAP on co-existing asthma in patients with OSA. We found evidence to support the hypothesis that CPAP significantly improves asthma-related quality of life. The majority of studies found that daytime or night-time asthma symptoms improve with CPAP. However, current evidence does not support an improvement in clinically significant asthma control using standardised measures such as the ACT or ACQ. CPAP does not improve lung function in this meta-analysis, but this finding is of unclear clinical significance in the asthmatic population The findings of this review are important because a high prevalence of OSA has been consistently reported in asthma, particularly within the severe asthma population 2 . Patients with severe asthma and co-existing OSA have been shown to have increased sputum neutrophil counts and evidence of airway remodelling 13 . Asthma patients with a neutrophilic rather than the typical eosinophilic phenotype are less likely to respond to with high dose inhaled corticosteroids or oral corticosteroids 13 . This review demonstrates that In five of the twelve studies 14, 15, 16, 17, 18 there was clear evidence of the application of robust asthma diagnostic criteria following international guidelines. Asthma severity was measured in two of the studies in accordance with current guidelines 19,17 but one of the studies 20 used patient-reported symptoms via a visual analogue scale. Polysomnography (PSG) is the goldstandard tool for the diagnosis of OSA and this was the case in eight of the studies. One study used limited-channel sleep studies in 70% and PSG in 30% of patients 14 , while one of the retrospective reviews used previous home limited-channel sleep study records 20 . Two cross-sectional questionnaire-based studies relied on records of a previous OSA diagnosis, however no information was provided concerning the diagnostic method used or the OSA severity. This raises questions about reliability of OSA diagnosis 19,21 . As previously mentioned, these two studies appear to include data from the same study population.
However, the two studies report different outcomes and have therefore both been reported in this review 19, 21 . It was reassuring to note that the majority of studies used PSG for the diagnosis of OSA, although limited-channel sleep studies are a well-recognised alternative.
The duration of CPAP treatment varied between studies and ranged from two weeks to twenty-five months for the prospective studies. OSA patients often take longer than a month to become fully complaint with CPAP and this could account for differences in results Asthma control is usually measured using the validated ACT 26 or ACQ 27 . There was significant heterogeneity in the study designs, populations and outcome measures which precluded meta-analysis of asthma control scores. Shaarawy et al used a prospective quasiexperimental study design with robust asthma diagnostic criteria and included a group of poorly controlled asthmatics 16 . Conversely, although the study population was much larger in the study by Kauppi et al, it was based on retrospective recall of symptoms and ACT pre-CPAP which was then compared to current ACT. The mean duration of CPAP was more than 5 years and therefore a significant risk of recall bias is present with this particular study 20 .
Four studies reported improvements in daytime and/or night-time asthma symptoms using different scoring systems or visual analogue scores, but without reporting formal ACT/ACQ scores, making it impossible to make comparisons 17,28-30 . Two studies (one using ACT and one using ACQ) found an improvement with CPAP, whereas one study (using ACT alone)
found no significant improvement. Serrano-Pariente et al demonstrated significant improvement in patients with either moderate-severe asthma or severe OSA at baseline 20 .
However it is important to note that a clinically significant improvement in mean ACQ(≥0.5) was not reached. Shaarawy et al 16 CPAP therapy can improve quality of life in patients with moderate-severe OSA, and it is logical that this can also impact on asthma related quality of life (AQLQ) and the improvement that has been seen in this review. It is difficult to fully separate quality of life improvements seen as a result of treating OSA, from improvements as a result of reduced asthma symptoms. This review has found conflicting evidence with regards to asthma control (ACQ) when CPAP treatment is used for co-existing OSA. Potential reasons for this M A N U S C R I P T
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include that CPAP may be poorly tolerated, particularly in severe asthma. The CPAP masks are recognised as being claustrophobic for some people, and this effect may be exacerbated in asthmatics who struggle with nocturnal symptoms of breathlessness and awakenings due to their asthma. Patients who feel reliant on medication at night might be concerned that the CPAP mask would make it harder to use their inhalers.
This systematic review's key strength is that it includes all study populations of asthmatics with co-existing OSA that have received CPAP treatment. We were able to evaluate a number of different asthma-related clinical outcomes including quality of life scores, asthma control/symptoms, asthma severity and lung function/physiological measures. Metaanalysis enabled pooled results of asthma quality of life scores and lung function.
Nevertheless, limitations include the small number of studies currently available, and heterogeneity of outcome measurements meant that meta-analysis was only possible in two of the clinical outcomes. Furthermore the individual studies did not report variability of change from pre-to post-CPAP values, so to enable meta-analysis the pre-and post-CPAP groups had to be analysed as independent groups which may have resulted in an overestimate of variability in each study. However, because we assumed greater variability than was present this is unlikely to have affected the overall trend of results as the improvement seen in AQLQ will still be at least as statistically significant as the result calculated. The lack of placebo-controlled studies should also be carefully considered when interpreting the results of this review. The placebo effect is well recognised within medical trials, and the CPAP device itself could act as powerful visual reminder for patients that they are receiving treatment.
Conclusion
In summary, this systematic review has demonstrated that CPAP treatment can improve asthma related quality of life and this effect appears more pronounced in severe OSA or poorly controlled asthma. Asthma symptoms and severity of asthma have also been shown to improve with CPAP but studies using standardised methods of measuring asthma control In younger subjects, CPAP attenuated the likelihood of worse asthma step by 58% 20% fall in FEV1 (≤8mgmL PC20) to methacholine No significant difference post CPAP; PC20 2.2 (95% CI 1.3-3.5) to 2.5 (95%CI 1.4-4.5), p=0.3 -A reduction in PC20 was noted in 3 patients -Baseline PC20 was significantly higher in those that showed improvement to those that did not; 7.3mgmL -1 vs. 
